Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
BACKGROUND
An oncolytic herpes simplex virus type 1 mutant (HF10) has been isolated and evaluated for antitumor efficacy in a syngeneic immunocompetent mouse model, where it was effective against cancer and conferred resistance to rechallenge with tumor cells in all surviving mice. Several studies have shown that HF10 is effective and safe for use against localized or peritoneally disseminated nonneuronal malignant tumors in animals.


METHODS
A pilot study using HF10 was initiated in six patients with cutaneous or subcutaneous metastases from breast cancer. For each patient, .5 mL of HF10 suspension containing various viral doses was injected into one nodule; .5 mL of sterile saline was injected into another. All patients were monitored for local and systemic adverse effects. Nodules were excised 14 days after injection for histopathologic studies.


RESULTS
All patients tolerated the intratumoral injection of HF10. No adverse effects occurred, and histopathological evaluation revealed 30% to 100% cancer cell death.


CONCLUSIONS
This pilot study found HF10 to be safe and effective against metastatic breast cancer.
Kimata
Hideto
H
Department of Surgery II, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Imai
Tsuneo
T
Kikumori
Toyone
T
Teshigahara
Osamu
O
Nagasaka
Tetsuro
T
Goshima
Fumi
F
Nishiyama
Yukihiro
Y
Nakao
Akimasa
A
D000368:Aged; D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D004195:Disease Models, Animal; D005260:Female; D018259:Herpesvirus 1, Human / Q000235:genetics*; D006801:Humans; D051379:Mice; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D050130:Oncolytic Virotherapy; D010865:Pilot Projects; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured